DDW’s Megan Thomas speaks with Dr Arun Upadhyay, Chief Scientific Officer, Head of Research & Development at Ocugen, about the development of gene-agnostic modifier therapies for inherited retinal diseases, highlighting pathway discovery, preclinical models, dosing strategies, biomarker integration, and the potential expansion of this approach beyond ophthalmology. MT: How does Ocugen identify and validate the […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!